GlassScriptPhysician profile
Tomasz J Niewiarowski
NPI 1073624441
$3,544.57
in general payments reported to CMS, 2019-2025
43 companies · $626 in 2025
The $626 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $107 · 2021: $572 · 2022: $386 · 2023: $747 · 2024: $856 · 2025: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,211 · Education: $17.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,211.04 |
| Education | $17.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $496.73 | 2021-2025 | Stelara, Remicade, Simponi Aria |
| Abbvie INC. | $324.85 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $322.37 | 2021-2025 | Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $235.78 | 2019-2025 | Entyvio, Fruzaqla |
| Daiichi Sankyo INC. | $230.16 | 2021-2025 | Enhertu, Injectafer |
| Celgene Corporation | $205.80 | 2021-2024 | Zeposia |
| Pfizer INC. | $152.28 | 2019-2025 | |
| Incyte Corporation | $121.37 | 2021-2025 | Niktimvo, Jakafi |
| Ferring Pharmaceuticals INC. | $107.87 | 2019-2024 | Rebyota |
| Allergan, INC. | $106.68 | 2019 | |
| Boston Scientific Corporation | $87.55 | 2019 | |
| Merck Sharp & Dohme LLC | $61.76 | 2024 | Keytruda, Dificid, Zinplava |
| Tempus Ai, INC | $56.36 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.94 | 2024-2025 | Xifaxan |
| Jazz Pharmaceuticals INC. | $55.19 | 2021-2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $53.93 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $53.63 | 2022-2025 | Ultomiris |
| Sobi, INC | $53.40 | 2024-2025 | |
| Emd Serono, INC. | $52.81 | 2023 | Bavencio |
| Epizyme, INC. | $51.05 | 2020-2021 | |
| Braintree Laboratories, INC. | $47.61 | 2021-2023 | Sutab |
| Gilead Sciences, INC. | $47.24 | 2021 | |
| Seagen INC. | $45.43 | 2023 | Padcev, Adcetris |
| Ardelyx, INC. | $45.25 | 2025 | Ibsrela |
| Echosens North America, INC. | $43.12 | 2021-2022 | |
| Puma Biotechnology, INC. | $42.54 | 2024-2025 | |
| Fresenius Kabi USA, LLC | $41.02 | 2024-2025 | Stimufend, Adalimumab-Aacf |
| Organon LLC | $32.04 | 2023 | Renflexis, Hadlima |
| Iovance Biotherapeutics, INC. | $31.26 | 2025 | Amtagvi |
| Glaxosmithkline, LLC. | $30.28 | 2024 | Ojjaara |
| Regeneron Healthcare Solutions, INC. | $30.04 | 2025 | Libtayo |
| Genmab U.S., INC. | $23.08 | 2023 | Epkinly |
| Teva Pharmaceuticals USA, INC. | $22.77 | 2025 | Simlandi |
| Exact Sciences Corporation | $22.45 | 2025 | Cologuard Collection Kit |
| Ipsen Biopharmaceuticals, INC | $19.44 | 2024 | Bylvay |
| Amgen INC. | $19.07 | 2020 | |
| Genzyme Corporation | $18.26 | 2024 | |
| Madrigal Pharmaceuticals | $18.19 | 2024 | Resmetirom |
| Celltrion USA INC. | $17.58 | 2024 | Zymfentra |
| Tersera Therapeutics LLC | $17.37 | 2024 | Zoladex |
| Phathom Pharmaceuticals, INC. | $16.57 | 2025 | Voquezna |
| Qol Medical, LLC | $15.02 | 2022 | |
| Medtronic, INC. | $13.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tomasz Niewiarowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.